Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety

Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety

Carlos De las Cuevas,1 Emilio J Sanz,2,3 Jose de Leon4,5 1Department of Internal Medicine, Dermatology, and Psychiatry and Instituto Universitario de Neurociencia (IUNE), Universidad de La Laguna, La Laguna, Canary Islands, Spain; 2Department of Physical Medicine and Pharmacology, Universidad de La...

Full description

Saved in:

Bibliographic Details
Main Authors:	De las Cuevas C, Sanz EJ, de Leon J
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-11-01
Series:	Patient Preference and Adherence
Subjects:	clozapine/adverse effects clozapine/therapeutic use clozapine/toxicity drug labeling product surveillance postmarketing schizophrenia
Online Access:	https://www.dovepress.com/pharmacovigilance-in-action-utilizing-vigibase-data-to-improve-clozapi-peer-reviewed-fulltext-article-PPA
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The effects of clinical and pharmacological factors on the ratio of clozapine to norclozapine in psychiatric patients
by: Anna Mach, et al.
Published: (2025-01-01)

The effect of clozapine on immune-related biomarkers in schizophrenia patients
by: Lu Shao, et al.
Published: (2024-11-01)

Successful utilization of clozapine for a patient with treatment‐resistant schizophrenia after recurrent violent behavior
by: Rikuto Christopher Shinohara, et al.
Published: (2024-09-01)

Clozapine-induced hypertension: A paradox
by: Hamza Hussain, et al.
Published: (2024-12-01)

The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
by: Hélène Verdoux, et al.
Published: (2025-01-01)

Prevalence of obsessive-compulsive symptoms in patients with schizophrenia treated with clozapine: a scoping review
by: Evelyn Moreno Tarazona, et al.
Published: (2025-01-01)

Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy
by: Dhandapani Nandakumar, et al.
Published: (2023-06-01)

A cross-sectional study to analyze the pattern of pharmacotherapy and its associated factors among patients with schizophrenia
by: B. S. Abhishree, et al.
Published: (2024-12-01)

Experience with and attitude toward clozapine use among patients receiving clozapine on long term and their caregivers
by: Sandeep Grover, et al.
Published: (2023-11-01)

Olanzapine-induced Pancytopenia: Case Report
by: A Prajnashree, et al.
Published: (2024-11-01)

Dropout rates and reasons for dropout among patients receiving clozapine
by: Sandeep Grover, et al.
Published: (2023-06-01)

Treatment of a schizophrenia patient on long-term super-dose antipsychotics: a case report
by: Xiaobo Xie, et al.
Published: (2025-01-01)

Prevalence and factors associated with high risk for obstructive sleep apnea in schizophrenia spectrum disorder patients on long-term clozapine
by: Rika Rijal, et al.
Published: (2024-12-01)

Manipulation of Lipid Nanocapsules as an Efficient Intranasal Platform for Brain Deposition of Clozapine as an Antipsychotic Drug
by: Ahmed A. Katamesh, et al.
Published: (2024-11-01)

Clozapine and Pneumonia: Synthesizing the Link by Reviewing Existing Reports—A Systematic Review and Meta-Analysis
by: Victor Zhao, et al.
Published: (2024-12-01)

Clozapine-carboxylic acid plasticized co-amorphous dispersions: Preparation, characterization and solution stability evaluation
by: Ali Ahmed Mahmoud Abdelhaleem, et al.
Published: (2015-06-01)

Predictors of clozapine efficacy in treatment-resistant schizophrenia: A cross-sectional analysis of sociodemographic, clinical, biochemical, and electrophysiological EEG changes
by: Sumaila Asif, et al.
Published: (2024-11-01)

Clozapine treatment of a Japanese patient during pregnancy: Effect on fetal heart rate
by: Shunya Aoki, et al.
Published: (2024-12-01)

Association between treatment resistance and cognitive function in schizophrenia
by: Jiaqian Sun, et al.
Published: (2024-10-01)

Prediction of drug-drug interactions in clozapine combination therapy based on physiologically based pharmacokinetic model
by: MOU Fan, et al.
Published: (2024-11-01)

A Simple HPLC-DAD Method for the Therapeutic Monitoring of Clozapine and Related Metabolites in Human Plasma and Urine Samples
by: Mircea-Alexandru Comănescu, et al.
Published: (2024-10-01)

Multipotent Effect of Clozapine on Lipopolysaccharide-Induced Acetylcholinesterase, Cyclooxygenase-2,5-Lipoxygenase, and Caspase-3: In Vivo and Molecular Modeling Studies
by: Minhajul Arfeen, et al.
Published: (2025-01-01)

Mapping of c-Fos Expression in Rat Brain Sub/Regions Following Chronic Social Isolation: Effective Treatments of Olanzapine, Clozapine or Fluoxetine
by: Andrijana Stanisavljević Ilić, et al.
Published: (2024-11-01)

Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence
by: Natalia Gniaź, et al.
Published: (2024-12-01)

Monitoring System of Medical Device Adverse Events in the US and Application of MAUDE Database in Medical Device Registration
by: Jing WU, et al.
Published: (2024-07-01)

Spontaneous adverse drug reactions reported in a thirteen-year pharmacovigilance program in a tertiary university hospital
by: E. Montané, et al.
Published: (2024-12-01)

Cardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database
by: Yusuke Igawa, et al.
Published: (2024-12-01)

A Blockchain-Based Post-Marketing Surveillance System for Medical Devices
by: Ali Tavakoli Golpaygani, et al.
Published: (2024-10-01)

Penerapan Komunikasi Terapeutik Pada Pasien Skizofrenia Dalam Mengontrol Halusinasi Di RS Jiwa Menur Surabaya
by: Yosi Apriliani, et al.
Published: (2020-10-01)

Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals
by: Charles Dolladille, et al.
Published: (2024-12-01)

Use of valproic acid in long stay units of psychiatry
by: Mª Teresa Martínez-Lazcano, et al.
Published: (2015-01-01)

Therapeutic Levels of Acetaminophen Causing AKI: A Case Report and Literature Review
by: Hamnah Tayyab, et al.
Published: (2025-01-01)

Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess
by: Yuanbin Huang, et al.
Published: (2024-12-01)

Brodalumab: Six-Year US Pharmacovigilance Report
by: Mark G. Lebwohl, et al.
Published: (2024-11-01)

Integrating pharmacovigilance into the routine of pharmacy department: experience of nine years
by: Ariadna Pérez-Ricart, et al.
Published: (2019-07-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022
by: Hui Liang, et al.
Published: (2025-01-01)

Adverse reactions after Covid-19 vaccination in persons affected by leprosy: A scoping review
by: Senthilkumar Ramasamy, et al.
Published: (2023-09-01)

Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases
by: Xianyu Dai, et al.
Published: (2025-01-01)

Multimodal prediction of the need of clozapine in treatment resistant schizophrenia; a pilot study in first-episode psychosis
by: Jonatan M. Panula, et al.
Published: (2024-12-01)